RLAY at a glance
Relay Therapeutics, Inc. (RLAY, SEC CIK 1812364) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Relay Therapeutics, Inc. (RLAY) reported revenue of $15.4 million (up 53.4% from FY2024) and a net loss of $276.5 million. Diluted EPS was -$1.61.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Relay Therapeutics, Inc. (RLAY) shares worth $1.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bergstrom Donald A on September 8, 2026 of 8,530 shares at $18.97 per share.
- In the last 90 days, RLAY insiders reported 0 open-market purchases ($0) and 10 open-market sales ($119.3M) on Form 4, a net sale of $119.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $15.4M
- +53.4% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$119.3M
- 13F holders
- 30 funds
- $1.7B · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02 · Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development
- Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals
- Dependence on third-party CROs and diagnostic partners, which may fail to meet contractual or regulatory requirements, delaying trials and companion diagnostics approval
- Competition for patient enrollment from other oncology trials, including Pfizer’s selective-CDK4 inhibitor in metastatic breast cancer combination study
- High operational risk from novel mechanism drug candidates requiring extensive R&D and potential unknown adverse effects raising development costs and regulatory hurdles
Management Discussion & Analysis
- Revenue $15.4M in 2025, up $5.3M YoY from $10.0M in 2024, primarily from Elevar Agreement milestones
- Net loss $276.5M in 2025 vs $337.7M in 2024; operating expenses down to $318.1M from $382.5M; R&D $261.4M vs $319.1M, G&A $56.7M vs $76.6M
- Best performing segment: License revenue from Elevar Agreement $15.4M in 2025; worst: Research & Development with $261.4M expense in 2025
- Cash, cash equivalents, investments $554.5M as of Dec 31, 2025; raised $218.2M net in Sept 2024 offering; no share sales under $250M ATM facility; no disclosed dividends or buybacks
- Management expects significant continued operating losses; cash runway into 2029; key risks include clinical trial progress, capital raising, regulatory approvals, and geopolitical/economic uncertainties
AI summary of the RLAY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New combination-therapy exposure: April 2026 Pfizer supply agreement depends on regulatory feedback for planned Phase 3 zovegalisib trial
- Regulatory risk: FDA may require a companion diagnostic for zovegalisib in a biomarker-defined population
- Clinical-development risk: No large-scale pivotal trial successfully completed
- Operational risk: Pfizer supply of atirmociclib and palbociclib supports planned Phase 3 combination trial
- Enrollment risk: Competitor trials and narrow biomarker eligibility may slow patient recruitment
AI summary of the RLAY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.2 with detailed financial results
Item 1.01: Entry into a Material Definitive Agreement
- ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales
- Approximately $162.98M already sold under the agreement, indicating substantial prior equity financing
Item EX-99.1: Item EX-99.1
- ATM equity-sales authorization increased from $250 million to $462,978,049, expanding potential financing capacity
- Additional share issuance creates dilution risk for existing shareholders and possible financing for operations or pipeline development
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Authorized common shares increased from 300 million to 450 million
- Stockholder approval received at the 2026 Annual Meeting
Item 5.07: Submission of Matters to a Vote of Security Holders
- Class III directors Douglas S. Ingram and Claire Mazumdar re-elected through 2029
- Executive compensation approved advisory basis, 143,849,919 votes for
Item 1.01: Entry into a Material Definitive Agreement
- $296.8M estimated net proceeds strengthen Relay’s funding capacity for clinical development and operations
- 26,354,167 shares sold at $12.00, including the fully exercised 3,437,500-share option
AI summaries of RLAY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RLAY
Don't miss the next RLAY filing
- Alerts as it files. A push when RLAY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RLAY, by share count.
- Ask anything. An AI agent that reads every RLAY filing and answers with sources.
RLAY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bergstrom Donald A | Sell | Sep 8, 2026 | 8,530 | $18.97 |
| Catinazzo Thomas | Sell | Sep 8, 2026 | 17,717 | $18.94 |
| Patel Sanjiv | Sell | Sep 8, 2026 | 48,199 | $18.94 |
| Rahmer Peter | Sell | Aug 26, 2026 | 4,508 | $20.03 |
| SVF Pauling (Cayman) Ltd | Sell | Aug 25, 2026 | 6,000,000 | $19.40 |
| Patel Sanjiv | Sell | Aug 17, 2026 | 48,199 | $20.33 |
| Catinazzo Thomas | Sell | Aug 14, 2026 | 17,717 | $19.74 |
| Rahmer Peter | Sell | Jul 28, 2026 | 748 | $18.61 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $25.5M | $10.0M | $15.4M |
| Operating Income | - | -$372.5M | -$302.7M |
| Net Income | -$342.0M | -$337.7M | -$276.5M |
| Op. Margin | - | -3722.1% | -1971.6% |
| Net Margin | -1338.7% | -3374.7% | -1800.6% |
| Balance Sheet | |||
| Total Assets | - | $871.3M | $621.3M |
| Equity | - | $777.8M | $567.1M |
| ROE | - | -43.4% | -48.8% |
| Per Share | |||
| EPS | $-2.79 | $-2.36 | $-1.61 |
| Cash Flow | |||
| Operating CF | - | -$249.1M | -$235.5M |
| CapEx | $4.1M | $2.0M | $410K |
Source: XBRL data in Relay Therapeutics, Inc. (RLAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RLAY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $1.69B |
| Q1 2026 | 29 | $523.5M |
| Q4 2025 | 24 | $404.4M |
| Q3 2025 | 27 | $241.1M |
| Q2 2025 | 28 | $186.4M |
| Q1 2025 | 25 | $106.2M |
| Q4 2024 | 21 | $139.0M |
| Q3 2024 | 18 | $118.9M |
- FMR LLC (Fidelity)+16.41M (+444%)
- T. Rowe Price Group+5.78M (+300%)
- State Street Corp+3.89M (+62%)
- Morgan Stanley+2.42M (+169%)
- BlackRock+2.31M (+18%)
- Two Sigma Investments−668.2K (-49%)
- Renaissance Technologies LLC−481.2K (-71%)
- Alphabet Inc−154.1K (-10%)
- AQR Capital Management−10.6K (-1%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RLAY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RLAY SEC filings: frequently asked questions
Are RLAY insiders buying or selling?
In the last 90 days, Relay Therapeutics, Inc. (RLAY) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $119.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RLAY stock?
As of June 30, 2026, the largest Relay Therapeutics, Inc. (RLAY) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($376.3 million), BlackRock ($286.0 million), State Street Corp ($189.5 million), Vanguard Capital Management LLC ($167.7 million), T. Rowe Price Group ($144.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RLAY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Relay Therapeutics, Inc. (RLAY) reported revenue of $15.4 million (up 53.4% from FY2024) and a net loss of $276.5 million. Diluted EPS was -$1.61. The figures come from the XBRL data in the 10-K.
What are the main risks in RLAY's latest 10-K?
In the 10-K filed February 26, 2026, Relay Therapeutics, Inc. (RLAY) flagged: FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development. Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals. (AI summary of the Risk Factors section.)
What did RLAY report in its latest 8-K?
Relay Therapeutics, Inc. (RLAY) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 1.01 (Entry into a Material Definitive Agreement). Q2 2026 results for quarter ended June 30, 2026.
What are the latest RLAY SEC filings?
Relay Therapeutics, Inc. (RLAY) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 9, 2026.
What is RLAY's SEC CIK number?
Relay Therapeutics, Inc. (RLAY)'s SEC Central Index Key (CIK) is 1812364. EDGAR lists every RLAY filing under that number.
Ask anything about RLAY
The research agent reads RLAY's filings, financials, insider trades and 13F holders, then answers with sources.